Previous Article | Next Article ![]()
Molecular and Cellular Biology, January 2002, p. 578-586, Vol. 22, No. 2
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.22.2.578-586.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Department of Biology, Boston University, Boston, Massachusetts 02215,1 Department of Biology, University Medical School of Pécs, Pécs, Hungary2
Received 4 April 2001/ Returned for modification 11 May 2001/ Accepted 15 October 2001
|
|
|---|
|
|
|---|
Previous studies have shown that Akt acts upstream of mitochondria to prevent cytochrome c release (27). Consistent with this site of action, one of the substrates of Akt that has been implicated in cell survival is the Bcl-2 family member Bad (12, 13). Phosphorylation by Akt inactivates Bad, preventing it from causing cytochrome c release. However, Akt has also been shown to promote the survival of cells in which Bad is not expressed (11) and to prevent the release of cytochrome c from mitochondria by mechanisms that are independent of Bad phosphorylation (27), indicating that Bad is not the only target of Akt responsible for cell survival. Akt has also been reported to inhibit apoptosis by phosphorylating human caspase 9 (7), but the lack of Akt phosphorylation sites in caspase 9 of other species limits the generality of this finding (20, 37). Additional targets of Akt that have been implicated in control of cell survival include the transcription factors Forkhead (5, 29), CREB (17), and NF-
B (26, 32, 35, 38), apoptosis signal-regulating kinase 1 (28), and glycogen synthase kinase 3ß (GSK-3ß) (36).
GSK-3ß is a ubiquitously expressed protein-serine/threonine kinase whose activity is inhibited by Akt phosphorylation (8). A role for GSK-3ß in regulating apoptosis downstream of PI 3-kinase/Akt signaling was first demonstrated in Rat-1 fibroblasts and PC12 pheochromocytoma cells (36). Overexpression of active GSK-3ß induced apoptosis of these cells, whereas expression of a dominant-negative mutant of GSK-3ß prevented apoptosis resulting from inhibition of PI 3-kinase (36). These results implicating GSK-3ß in cell survival have subsequently been extended to other cell types, including primary neurons both in culture and in the brains of transgenic mice (1, 9, 24, 31, 33). Inhibition of GSK-3ß as a result of phosphorylation by protein kinase A has also been shown to contribute to the promotion of neuronal survival by cyclic AMP (30).
GSK-3ß phosphorylates a variety of substrates, including glycogen synthase and other metabolic enzymes, ß-catenin, transcription factors, and the translation initiation factor eIF2B (43). Initially identified as a regulator of glycogen synthesis, GSK-3ß plays an important physiological role in coupling metabolism and protein synthesis to growth factor stimulation (42, 43). Because of the central role of protein synthesis in maintaining cell functions, we have investigated the involvement of translational regulation in cell survival mediated by the PI 3-kinase/Akt/GSK-3ß signaling pathway. Phosphorylation of the
subunit of eIF2B by GSK-3ß results in its inactivation and subsequent inhibition of translation initiation (42). The GSK-3ß phosphorylation site is conserved and regulates the activity of eIF2B in insects as well as several mammalian species (42, 44). We report here that expression of a mutant eIF2B lacking the GSK-3ß phosphorylation site prevents apoptosis induced by overexpression of GSK-3ß, inhibition of PI 3-kinase, or growth factor deprivation. Consistent with this, inhibition of translation by cycloheximide was sufficient to induce apoptosis in a number of cell lines. Moreover, inhibition of translation resulting either from treatment with cycloheximide or from phosphorylation of eIF2B by GSK-3ß led to the release of cytochrome c from mitochondria, consistent with previously reported effects of Akt on cytochrome c release (27). Translational regulation resulting from phosphorylation of eIF2B by GSK-3ß thus appears to play a key role in the control of programmed cell death by the PI 3-kinase/Akt signaling pathway.
|
|
|---|
Plasmids and site-directed mutagenesis.
cDNAs encoding wild-type rat GSK-3ß, wild-type rat eIF2B
(provided by T. Herbert, University of Dundee, Dundee, United Kingdom), mutant S535A eIF2B, mutant S539A eIF2B, Flag-tagged wild-type and S535A eIF2B, and human tau (provided by K. S. Kosik, Brigham and Womens Hospital, Boston, Mass.) were transcribed from the cytomegalovirus promoter in pcDNA3. cDNA encoding dominant-negative PI 3-kinase
p85 (15) was transcribed from the SR
promoter (provided by C. Rudd, Dana-Farber Cancer Institute). Site-directed mutagenesis of rat eIF2B
cDNA was performed with the QuikChange Site-Directed Mutagenesis Kit (Stratagene) to change Ser535 (the GSK-3ß phosphorylation site in rat eIF2B) (18, 42) to Ala using the primer 5'-CCCGAGGAGCTGGACGCCCGAGCAGGCTCCCC-3' and to change Ser539 (the priming site for phosphorylation by GSK-3ß) to Ala using the primer 5'-GCCGAGCAGGCGCCCCTCAGCTGGATGAC-3'. The constructs were sequenced to confirm that only the intended point mutations were introduced.
Transfection and apoptosis assays. A total of 105 cells were plated on poly-l-lysine-treated coverslips in 35-mm-diameter plates 24 h before transfection. Transfections were performed using 4 µl of Lipofectamine Reagent (Life Technologies, Inc.)/plate according to the manufacturers instructions. Cells were transfected with 0.5 µg of pcDNA3 or the indicated GSK-3ß, eIF2B, or PI 3-kinase expression construct plus 0.5 µg of the green fluorescent protein (GFP) expression construct pEGFP-C1 (Clontech). Two days after transfection, cells were fixed and stained with 0.5 µg of the DNA dye bisbenzimide (Hoechst 33258)/ml. Transfected cells were identified by GFP fluorescence and scored for apoptosis by nuclear morphology as previously described (36). Typically, 100 to 150 cells transfected with each vector were counted per experiment.
Immunoblot analysis. PC12 cells were transfected on the day after plating. One or two days after transfection, cells were lysed, and 50 or 100 µg of proteins was electrophoresed in sodium dodecyl sulfate12% polyacrylamide gels and transferred to nitrocellulose membranes. Membranes were incubated with the indicated primary antibodies, followed by incubation with a horseradish peroxidase-conjugated secondary antibody. Proteins were identified using the ECL system (Amersham Life Science Inc.).
Isolation of transfected cells by cell sorting. A total of 3 x 106 PC12 cells were plated in 100-mm plates and transfected the following day with 4 µg of control (pcDNA3), wild-type eIF2B, or S535A eIF2B expression plasmids plus 4 µg of the GFP expression plasmid pEGFP-C1 using 80 µl of Lipofectamine Reagent/plate. One or two days after transfection, cells were trypsinized, resuspended in phosphate-buffered saline (PBS), and sorted for GFP fluorescence in a FACScan (Becton Dickinson) flow cytometer. A total of 105 cells expressing high levels of GFP were collected and plated in a 48-well plate for use in assays of protein synthesis.
Analysis of translation. PC12 or Rat-1 cells were incubated with 10 µCi of [35S]methionine/ml for 2 or 3 h. Cells were collected, protein was precipitated with 10% trichloroacetic acid, and incorporation of [35S]methionine was determined by scintillation counting.
Cytochrome c release. Cells were fixed in 4% formaldehyde in PBS for 10 min, permeabilized by treatment with 0.5% Triton X-100 in PBS for 5 min on ice, and incubated in blocking buffer (5% goat serum and 1% bovine serum albumin in PBS) for 1 h. Coverslips were first incubated for 1 h with anti-cytochrome c antibody (6H2.B4; PharMingen) diluted 1:100 in blocking buffer and were then incubated for 1 h in the dark with CY3-conjugated anti-mouse immunoglobulin G (Sigma) diluted 1:200 in blocking buffer. Cells with diffuse staining, in contrast to the localized thread-like staining consistent with mitochondrial cytochrome c, were scored as having released cytochrome c from mitochondria (3). Cells were photographed using a Bio-Rad confocal microscope.
|
|
|---|
subunit of eIF2B in both mammalian and insect cells, resulting in its inactivation and subsequent inhibition of the initiation of translation (42, 44). We confirmed that eIF2B was phosphorylated at this site in both PC12 and Rat-1 cells by immunoblotting with a phosphospecific peptide antibody (42) (data not shown). To determine whether phosphorylation of eIF2B by GSK-3ß plays a role in control of cell survival, we then generated a nonphosphorylatable mutant of rat eIF2B (S535A) in which the serine residue phosphorylated by GSK-3ß was changed to alanine. PC12 and Rat-1 cells were cotransfected with plasmids expressing wild-type or S535A eIF2B together with a GSK-3ß expression plasmid and a plasmid expressing GFP. Transfected cells were identified by fluorescence microscopy to detect GFP expression and were scored for apoptosis by nuclear morphology after staining with Hoechst dye as previously described (36). As previously reported (36), expression of GSK-3ß induced apoptosis in approximately 60% of the transfected cells (Fig. 1A). A similar level of apoptosis was observed when cells were cotransfected with plasmids expressing GSK-3ß and wild-type eIF2B. In contrast, expression of the nonphosphorylatable mutant S535A eIF2B protected cells from apoptosis induced by GSK-3ß expression, reducing the level of apoptosis in both Rat-1 and PC12 cells to the background levels obtained in control cultures. The wild-type and mutant eIF2Bs were expressed at similar levels (Fig. 1B), indicating that the activity of the S535A eIF2B mutant in suppressing apoptosis did not result from differential expression compared to the wild-type protein. Inhibition of translation as a result of phosphorylation of eIF2B thus appears to play a critical role in cell death induced by GSK-3ß.
![]() View larger version (24K): [in a new window] |
FIG. 1. (A) Nonphosphorylatable mutant S535A eIF2B inhibits apoptosis induced by GSK-3ß. PC12 and Rat-1 cells were cotransfected with 0.5 µg of pcDNA3 or the indicated GSK-3ß, wild-type rat eIF2B (wt eIF2B), and mutant S535A eIF2B expression constructs plus 0.5 µg of the GFP expression construct pEGFP-C1. Two days after transfection, cells were fixed and stained with Hoechst dye. Transfected cells were identified by GFP fluorescence and scored for apoptosis by nuclear morphology. Data are averaged from three independent experiments. Error bars, standard deviations. (B) A total of 8 x 105 PC12 cells were plated into 60-mm plates and transfected the following day with 4 µg of pcDNA3 or FLAG-tagged wild-type or mutant S535A eIF2B expression constructs using 50 µl of Lipofectamine Reagent/plate. Two days after transfection, cells were lysed and 50 µg of proteins was analyzed by immunoblotting with a monoclonal anti-FLAG M5 antibody (10 µg/ml; Sigma).
|
![]() View larger version (31K): [in a new window] |
FIG. 2. Effect of S535A eIF2B on apoptosis induced by PI 3-kinase inhibition or serum deprivation. Cells were cotransfected with expression plasmids for wild-type or S535A mutant eIF2B or for dominant-negative PI 3-kinase (dnPI3K) plus pEGFP-C1. Two days after transfection, cells were either left untreated, treated with 50 µM LY294002, or deprived of serum for 24 h; then they were fixed and stained with Hoechst dye. Transfected cells were identified by GFP fluorescence and scored for apoptosis by nuclear morphology. Data are averaged from three independent experiments.
|
![]() View larger version (28K): [in a new window] |
FIG. 3. Effect of overexpression of wild-type or mutant eIF2B on GSK-3ß phosphorylation of tau. A total of 5 x 106 PC12 cells were plated into 100-mm plates and transfected the following day with 9 µg of DNA using 100 µl of Lipofectamine Reagent/plate. Where indicated, cells were transfected with 1.2 µg of tau expression plasmid, 6 µg of GSK-3ß expression plasmid, and 1.2 µg of expression constructs for wild-type or S535A mutant eIF2B, plus pcDNA3 to a total of 9 µg of DNA. One day after transfection, cells were lysed and 100 µg of proteins was analyzed by immunoblotting with a polyclonal anti-tau (pS396) phosphospecific antibody (0.4 µg/ml; BioSource) or with a monoclonal anti-tau antibody (1 µg/ml; BioSource).
|
![]() View larger version (39K): [in a new window] |
FIG. 4. Effect of priming site mutant S539A eIF2B on apoptosis induced by GSK-3ß or PI 3-kinase inhibition. PC12 and Rat-1 cells were transfected with the indicated expression plasmids as described for Fig. 1. Data are averaged from two to four independent experiments.
|
![]() View larger version (22K): [in a new window] |
FIG. 5. Effect of S535A eIF2B on translation following inhibition of PI 3-kinase. A total of 3 x 106 PC12 cells were transfected either with a control (pcDNA3) or with a wild-type eIF2B or S535A eIF2B expression plasmid plus the GFP expression plasmid pEGFP-C1. One or two days after transfection, cells were sorted for GFP fluorescence in a flow cytometer. A total of 105 cells expressing high levels of GFP (indicated by the horizontal line in panel A) were plated in a 48-well plate. The following day, cells were treated with 50 µM LY294002 for 4 h and then labeled with 10 µCi of [35S]methionine/ml for 3 h. Data are presented (B) as the percent [35S]methionine incorporation (percent translation activity) in cells treated with LY294002 compared to untreated controls. Data are averaged from three independent experiments with duplicate samples.
|
Induction of apoptosis by cycloheximide. The ability of S535A eIF2B to maintain protein synthesis and to protect cells from apoptosis following inhibition of PI 3-kinase indicates that translational regulation plays an important role in cell survival. We further investigated the role of protein synthesis in apoptosis by treating cells with cycloheximide, a general inhibitor of translation. PC12 and Rat-1 cells were treated with varying doses of cycloheximide, followed by analysis of protein synthesis by [35S]methionine incorporation and of apoptosis by nuclear morphology. As previously reported for other cell types (2, 34, 40), inhibition of protein synthesis by cycloheximide induced apoptosis of both PC12 and Rat-1 cells (Fig. 6), consistent with a requirement for translation in cell survival. Similar induction of apoptosis as a result of inhibiting protein synthesis with cycloheximide was also observed in HeLa, MCF7, U937, and 293T cells (data not shown).
![]() View larger version (25K): [in a new window] |
FIG. 6. Induction of apoptosis by cycloheximide. For assays of protein synthesis (filled circles), 106 PC12 and Rat-1 cells were plated in 100-mm plates, treated the following day with the indicated concentrations of cycloheximide (CHX) for 30 min, labeled with 10 µCi of [35S]methionine/ml for 2 h, and analyzed by trichloroacetic acid precipitation. Data are averaged from three independent experiments, each with duplicate samples. For analysis of apoptosis (open circles), 105 cells were plated on poly-l-lysine-treated coverslips in 35-mm plates and treated with cycloheximide the following day for 16 h. Cells were then stained with Hoechst dye and scored for apoptosis by nuclear morphology. Data are averaged from three independent experiments.
|
![]() View larger version (33K): [in a new window] |
FIG. 7. S535A eIF2B does not affect apoptosis induced by cycloheximide. Cells were transfected with a control, wild-type eIF2B, or mutant S535A eIF2B expression plasmid plus the GFP expression plasmid pEGFP-C1. Two days after transfection, cells were treated with 10 µg of cycloheximide (CHX)/ml for 24 h and then stained with Hoechst dye, and GFP-positive cells were scored for apoptosis by nuclear morphology. Data are averaged from three independent experiments.
|
![]() View larger version (54K): [in a new window] |
FIG. 8. Inhibition of translation induces cytochrome c release. (A) A total of 105 PC12 cells were plated on poly-l-lysine-treated coverslips in 35-mm plates and treated the following day with either LY294002 (50 µM; middle panel) or cycloheximide (10 µg/ml; right panel) for 6 h. (Left panel) Control. Cells were analyzed for cytochrome c release by anti-cytochrome c immunostaining, and representative fields were photographed with a confocal microscope. (B) Cells were treated for the indicated times with LY294002 or cycloheximide (CHX) and analyzed for cytochrome c release by immunostaining. Data are averaged from three independent experiments.
|
![]() View larger version (53K): [in a new window] |
FIG. 9. Effect of S535A eIF2B on cytochrome c release. PC12 cells were transfected with a control (pcDNA3), wild-type eIF2B, or mutant S535A eIF2B expression plasmid plus pEGFP-C1. Two days after transfection, cells were treated with either LY294002 (50 µM) or cycloheximide (CHX; 10 µg/ml) for 6 h. Transfected cells were identified by GFP fluorescence (upper panels) and analyzed for release of cytochrome c using an anti-cytochrome c antibody (lower panels). Confocal images of a representative experiment are shown.
|
![]() View larger version (57K): [in a new window] |
FIG. 10. Quantitation of effects of S535A eIF2B on cytochrome c release. PC12 cells were transfected with a control (Con), wild-type eIF2B, or S535A eIF2B expression plasmid plus pEGFP-C1, treated with LY294002 or cycloheximide (CHX), and analyzed for cytochrome c release as described for Fig. 9. Data are averaged from four independent experiments.
|
B (26, 32, 35, 38), and the protein kinase GSK-3ß (36). In the present study, we demonstrate that GSK-3ß controls cell survival, at least in part, as a result of phosphorylation of translation initiation factor eIF2B and global regulation of protein synthesis. GSK-3ß, the first characterized physiological substrate of Akt, was initially identified as a protein kinase that regulates glycogen synthesis in response to insulin signaling. Subsequent studies have shown that GSK-3ß is a ubiquitously expressed protein kinase whose activity is inhibited by Akt phosphorylation in response to stimulation of cells by a variety of growth factors (8). A role for GSK-3ß in cell survival was initially indicated by experiments showing that overexpression of active GSK-3ß induced apoptosis of PC12 and Rat-1 cells, whereas expression of a dominant-negative mutant of GSK-3ß was sufficient to prevent apoptosis following inhibition of PI 3-kinase (36). These results have been confirmed and extended to several other cell types, including primary neurons both in culture and in transgenic mice (1, 4, 9, 24, 30, 31, 33), indicating that GSK-3ß is an important target of the PI 3-kinase/Akt pathway in signaling cell survival.
The substrates of GSK-3ß include metabolic enzymes, several transcription factors, ß-catenin, and the translation initiation factor eIF2B (43). Phosphorylation by GSK-3ß inactivates eIF2B, leading to an inhibition of translation in the absence of growth factor stimulation of the PI 3-kinase/Akt pathway. In the present study, we have shown that expression of eIF2B mutants lacking the GSK-3ß phosphorylation or priming sites is sufficient to maintain both cell survival and protein synthesis following inhibition of PI 3-kinase signaling. Expression of nonphosphorylatable eIF2B mutants inhibited apoptosis resulting from either overexpression of active GSK-3ß, inhibition of PI 3-kinase, or withdrawal of serum growth factors, indicating a critical role for translational regulation in prevention of apoptosis by PI 3-kinase/Akt signaling.
Consistent with such a requirement for translation in cell survival, inhibition of protein synthesis with cycloheximide induced apoptosis of Rat-1 cells, PC12 cells, and several human cell lines, as has been previously reported for human HL60 leukemia cells (34), rat hepatocytes (2), and human T-cell lines (40). A role for translational regulation in cell survival is also consistent with the findings of previous studies indicating that inhibition of translation resulting from phosphorylation of the
subunit of initiation factor eIF2 is involved in apoptosis induced by the double-stranded RNA-activated protein kinase PKR (21, 39).
Previous studies have shown that PI 3-kinase/Akt signaling acts upstream of mitochondria to prevent the release of cytochrome c and subsequent activation of cytosolic caspases (27). Expression of the nonphosphorylatable eIF2B mutant prevented cytochrome c release following inhibition of PI 3-kinase, whereas inhibition of translation with cycloheximide induced cytochrome c release. Regulation of translation resulting from phosphorylation of eIF2B thus appears to affect the apoptotic cascade upstream of mitochondria, consistent with eIF2B serving as a target of PI 3-kinase/Akt signaling in the prevention of apoptosis.
It is clear that multiple targets of Akt are important in regulating cell survival (11), and additional targets of GSK-3ß may also play significant roles. In the Wnt signaling pathway, GSK-3ß phosphorylates ß-catenin, which has been implicated in neuronal apoptosis induced by ß-amyloid peptide (48). However, overexpression of either ß-catenin or its associated transcription factor TCF does not protect cortical neurons or PC12 cells from apoptosis induced by growth factor deprivation or GSK-3ß overexpression (24; M. Pap and G. M. Cooper, unpublished data). As a component of Wnt signaling, GSK-3ß may also contribute to regulation of NF-
B transcription factors, with proapoptotic effects in some cells and antiapoptotic effects in others (4, 25). These differences may be related to the fact that the PI 3-kinase/Akt and Wnt pathways regulate GSK-3ß by distinct mechanisms and may induce the phosphorylation of different target proteins (16, 19). In contrast to these cell-specific effects, the global regulation of protein synthesis is a common response of cells to growth factor stimulation. Regulation of translation by the PI 3-kinase/Akt/GSK-3ß pathway may thus represent a general mechanism of cell survival signaling, coupling mitochondrial integrity and cytochrome c release to the central metabolic activity of protein synthesis.
This work was supported by NIH grant RO1 CA18689.
|
|
|---|
B in PC12 cells. J. Neurosci. Res. 61:2132.[CrossRef][Medline]
subunit of eukaryotic translation initiation factor 2 and NF-
B. Mol. Cell. Biol. 19:46534663.
B activation. Nature 406:8690.[CrossRef][Medline]
B by the Akt/PKB kinase. Curr. Biol. 9:601604.[CrossRef][Medline]
B. Mol. Cell. Biol. 20:16261638.
B activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401:8285.[CrossRef][Medline]
B is a target of AKT in anti-apoptotic PDGF signalling. Nature 401:8689.[CrossRef][Medline]
-subunit and their functions in vivo. EMBO J. 20:43494359.[CrossRef][Medline]
at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem. J. 355:609615.[CrossRef][Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»